Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP4 | Q13107 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30944564 | 0.89 | MEN1 (0.41) | POLBTP53THRBALDH1A1HPGD | |
| SCHEMBL19633220 | 0.84 | ERBB2 (0.40) | USP4USP7POLBTP53ALDH1A1 | |
| SCHEMBL19633223 | 0.84 | NAMPT (0.43) | USP4USP7KDM4EL3MBTL1 | |
| SCHEMBL19636936 | 0.84 | ERBB2 (0.40) | USP4USP7POLBTP53ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL30944531 | 0.79 | POLB (0.35) | POLBTP53THRBSMN1; SMN2MEN1 | |
| SCHEMBL25855375 | 0.79 | POLB (0.34) | USP4USP7POLBTP53THRB | |
| SCHEMBL19636845 | 0.77 | ERBB2 (0.40) | KDM4E | |
| SCHEMBL19633055 | 0.77 | NAMPT (0.38) | MEN1KMT2AKDM4E | |
| SCHEMBL19636934 | 0.77 | ERBB2 (0.41) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31615259 | 0.75 | P2RY12 (0.44) | POLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | USP4 2839/4885USP7 2915/4885POLB 861/4885 |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | USP4 2839/4885USP7 2915/4885POLB 861/4885 |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD79B, CLTB, FCGR3B | USP4 2839/4885USP7 2915/4885POLB 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.